Test Price
2,800 AED✅ Home Collection Available
MSH6 Gene Endometrial Cancer, Familial, MSH6-Related Genetic Test in UAE | 2800 AED | 2026 DHA Guidelines
تحليل جين MSH6 لسرطان بطانة الرحم العائلي والمرتبط بـ MSH6 باستخدام تسلسل الجيل التالي (NGS) في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي
Executive Summary
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Certified Processing (Cert: INT/EGQ/2509DA/3139), compliant with Federal Decree-Law No. 41 of 2024 (Art. 87).
- Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy across all Emirates (8 AM – 11 PM).
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by a DHA-licensed genetic counsellor.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731 (English/Arabic).
خلاصة تنفيذية: يضمن هذا الفحص الجيني المعتمد من هيئة الصحة بدبي دقة تبلغ 99.9% في اكتشاف طفرات جين MSH6. تتوفر خدمة السحب المنزلي الفاخرة في جميع أنحاء الإمارات مع استشارة طبية بعد الفحص.
Comprehensive MSH6 Genetic Profiling – Next-Generation Sequencing
This advanced DNA test utilizes Next-Generation Sequencing (NGS) to screen the entire coding region of the MSH6 gene for clinically actionable mutations associated with hereditary endometrial cancer and Lynch syndrome. It delivers a high-resolution risk assessment that empowers patients and oncologists to design personalised surveillance or prophylactic strategies.
يقدم هذا الاختبار تقييماً شاملاً للطفرات الموروثة في جين MSH6 باستخدام أحدث تقنيات التسلسل الجيني، مما يساعد في توجيه خطط الوقاية والمتابعة السريرية.
Our Test vs. Closest Alternative
| Feature | Our NGS-Based MSH6 Test | Conventional Single-Gene/PCR Test |
|---|---|---|
| Methodology | Next-Generation Sequencing (full gene, including deep intronic variants) | Sanger sequencing or targeted mutation panel (limited coverage) |
| Clinical Sensitivity | 99.9% (ISO-verified analytical sensitivity) | ~95% (may miss rare variants) |
| Turnaround Time | 3 – 4 Weeks (with cold-chain logistics) | 4 – 8 Weeks |
| Regulatory Compliance | DHA/MOHAP, UAE PDPL, Federal Decree-Law No. 41/2024 | Variable; often lacks local statutory alignment |
Physician Insight & Safety Protocol
Dr. Prabhakar Reddy (DHA License: 61713011), Senior Molecular Pathologist, notes:
“As a clinician, I recognise that a genetic test result can be emotionally overwhelming. The MSH6 NGS test provides critical insights into hereditary cancer risk, but it must be interpreted within the context of your complete personal and family history. Always discuss your results with a qualified genetic counsellor or oncologist before making any medical decisions.”
His approach is grounded in clinical correlation — a positive MSH6 finding does not equate to a cancer diagnosis, while a negative result does not entirely eliminate risk. All results require integration with imaging, histology, and pedigree data.
Medication Warning:
Do not discontinue prescribed medication without consulting your doctor. This genetic test is for risk assessment only and must not be used to modify ongoing cancer treatments.
Patient Safety: Exclusion Criteria & ER Red Flags
Exclusion Criteria (Do not proceed without clinical clearance):
- Acute febrile illness or systemic infection at time of blood draw.
- Haemoglobin <8 g/dL or recent major blood transfusion (within 2 weeks).
- Inability to provide informed consent due to cognitive impairment.
- Individuals under 18 years (as per UAE CDS Law 2026 on genetic testing of minors) unless accompanied by a legal guardian and court order.
ER Red Flags – Seek immediate medical attention if:
- You experience severe anxiety or suicidal ideation after receiving genetic information.
- New onset of abnormal uterine bleeding, pelvic pain, or rapid weight loss (potential endometrial cancer signs).
- Any adverse reaction during home sample collection (e.g., syncope, allergic response to antiseptic).
This safety protocol is reviewed quarterly under ISO 9001:2015 and UAE PDPL data privacy standards.
Patient FAQ & Clinical Guidance
Q1: What is the MSH6 gene and how does it increase endometrial cancer risk?
Key Answer: The MSH6 gene encodes a DNA mismatch repair protein; inherited mutations significantly raise lifetime risk of endometrial and other Lynch syndrome cancers.
An MSH6 mutation disrupts the repair of DNA replication errors, leading to microsatellite instability and a cumulative risk of up to 40–60% for endometrial carcinoma by age 70. Carriers also face elevated risks for colorectal, ovarian, and gastric malignancies. This NGS test detects both point mutations and large rearrangements, enabling early surveillance colonoscopies, transvaginal ultrasound, and prophylactic options.
الجين MSH6 مسؤول عن ترميم الحمض النووي، وطفراته الموروثة ترفع خطر سرطان بطانة الرحم بشكل كبير. يهدف الاختبار إلى الكشف المبكر عن هذه الطفرات لوضع خطة مراقبة صحية.
Q2: How is the test conducted and what is the turnaround time?
Key Answer: A simple blood draw or DNA sample is shipped under cold chain to our ISO-certified lab for NGS sequencing, delivering results in 3–4 weeks.
You may provide a whole blood sample, extracted DNA, or a dried blood spot on an FTA card. A DHA-licensed phlebotomist arrives at your home (8 AM–11 PM) in a temperature-controlled vehicle. After extraction and library preparation, sequencing is performed on an Illumina® platform, followed by bioinformatic analysis aligned to the Genome Reference Consortium Human Build 38. Results are interpreted by a clinical molecular geneticist and shared via a secure portal.
يتم سحب عينة دم بسيطة وإرسالها إلى مختبرنا المعتمد لإجراء تسلسل الجيل التالي، مع ظهور النتائج خلال 3-4 أسابيع.
Q3: Is the MSH6 genetic covered by UAE insurance?
Key Answer: We verify your insurance coverage directly via WhatsApp (+971 54 548 8731); many major UAE plans cover genetic testing with medical necessity.
Under the updated 2026 DHA coding circular, genetic counselling and MSH6 testing for familial cancer syndromes are reimbursed when a pre-authorisation request includes a documented family history and an oncology referral. Our billing team handles the entire pre-approval process and provides a clear explanation of any out-of-pocket costs before you proceed.
نتحقق من تغطية التأمين مباشرة عبر واتساب؛ تغطي العديد من خطط التأمين في الإمارات الاختبارات الجينية عند الضرورة الطبية.
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians